title: Randomized, controlled, evaluator-blinded studies conducted to compare the efficacy and tolerability of 3 over-the-counter acne regimens in subjects with mild or moderate acne.
abstract: BACKGROUND
  Acne vulgaris is a common dermatologic disease that most frequently affects adolescents and young adults. Over-the-counter (OTC) acne treatment regimens are increasingly being used by individuals with acne.
  
  
  OBJECTIVE
  To compare the efficacy, user satisfaction, and tolerability of the OTC regimens MaxClarity™, Proactiv®, and Murad® in the treatment of mild and moderate acne.
  
  
  METHODS
  Two randomized, evaluator-blinded, split-face studies were conducted, each involving 20 subjects with acne, to evaluate MaxClarity against Proactiv (study 401) and MaxClarity against Murad (study 404) over 8 weeks.
  
  
  RESULTS
  Clinically and statistically significant reductions in acne lesion counts were achieved at 8 weeks compared with baseline for each regimen using MaxClarity, Proactiv, and Murad. Similar reductions in lesion counts and improvements in Investigator's Static Global Assessment grades were observed between MaxClarity and either Proactiv or Murad, in the respective studies. MaxClarity was well tolerated, with no treatment-related adverse events observed in any treatment group and no discontinuations due to adverse events. Overall, most subjects were satisfied with all study treatments.
  
  
  CONCLUSIONS
  MaxClarity is an effective alternative to either Proactiv or Murad for use in the treatment of mild and moderate acne.
authors: George Washington University School of Medicine, Washington, DC, USA.
authors: Lawrence
authors: L
authors: Green
authors: Leon H
authors: LH
authors: Kircik
authors: Jennifer
authors: J
authors: Gwazdauskas
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D044466:Asian People; D001585:Benzoyl Peroxide / Q000008:administration & dosage / Q000627:therapeutic use; D044383:Black People; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005145:Face / Q000473:pathology; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D004366:Nonprescription Drugs; D010349:Patient Compliance; D057240:Patient Preference; D061214:Patient Safety; D020156:Salicylic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome; D044465:White People; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; D007641:Keratolytic Agents; D004366:Nonprescription Drugs; D020156:Salicylic Acid; D001585:Benzoyl Peroxide